🇺🇸 FDA
Patent

US 11236171

Human monoclonal antibodies specific for FLT3 and uses thereof

granted A61KA61K2039/505A61K47/6849

Quick answer

US patent 11236171 (Human monoclonal antibodies specific for FLT3 and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/505, A61K47/6849, A61K47/6929, A61P